Open label, multiple dose, sequential, drug-drug interaction study to assess the pharmacokinetics and safety of atazanavir and raltegravir co-administered twice daily in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2008
At a glance
- Drugs Atazanavir; Raltegravir
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 05 Nov 2008 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 10 Sep 2007 Status changed from initiated to recruiting.
- 28 Aug 2007 New trial record.